Skip to main content
. Author manuscript; available in PMC: 2017 Aug 15.
Published in final edited form as: Mol Oncol. 2017 May 30;11(8):981–995. doi: 10.1002/1878-0261.12066

Figure 6. MLN8237 alone or in combination with CDDP effectively reduces resistant cells-derived xenograft growth in vivo.

Figure 6

MKN45 cells-derived xenograft tumors (150–200 mm3 in size) were treated with CDDP (2.5 mg/kg, once a week) alone, MLN8237 (40 mg/kg, 5 times a week) alone or the combination of CDDP and MLN8237 for 28 days and tumor sizes were measured twice a week (A, B) The data indicated that MLN8237 alone or in combination with CDDP has a significant anti-tumor activity against resistant MKN45 cells-derived xenografts. (C) Tumor tissue lysates were subjected to Western blot analysis of the indicated proteins. (D) IHC analysis of MKN45 cells-derived xenografts showing ki67 and cleaved caspase-3 expressions in vivo. Relative integrated density indicates the quantification data of immunostaining signal which was calculated by Image J software; **p<0.01, ***p<0.001.